Posted On: 07/31/2014 6:01:55 PM
Post# of 30066
It's really quite simple.
The market was expecting LymPro numbers for sensitivity and specificity that would clearly make it the "gold standard" for Alzheimer's detection. Unfortunately it appears that in diagnostic terms it was marginally better than a "coin-flip".
Here again this is my opinion and I'm not qualified as a scientist to extrapolate the available information to a meaningful conclusion. I'll let others on the board do that.
As for increasing the number of authorized shares by 50% or a 100% I don't see another alternative but then again I'm not a financial type individual. I am barely able to balance my checkbook.
The market was expecting LymPro numbers for sensitivity and specificity that would clearly make it the "gold standard" for Alzheimer's detection. Unfortunately it appears that in diagnostic terms it was marginally better than a "coin-flip".
Here again this is my opinion and I'm not qualified as a scientist to extrapolate the available information to a meaningful conclusion. I'll let others on the board do that.
As for increasing the number of authorized shares by 50% or a 100% I don't see another alternative but then again I'm not a financial type individual. I am barely able to balance my checkbook.
(0)
(0)
